Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Sigilon Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/15/2023 |
4
| Flagship Ventures Fund V General Partner LLC (10% Owner) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Unknown transaction of 683,760 shares
@ $14.92, valued at
$10.2M
Unknown transaction of 113,960 shares
@ $14.92, valued at
$1.7M
|
|
| 08/14/2023 |
4
| ELI LILLY & Co (10% Owner) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Bought 1,718,493 shares
@ $14.92, valued at
$25.6M
|
|
| 08/11/2023 |
4
| Cole Douglas G. (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 683 options to buy
@ $6.6439, valued at
$4.5k
Disposed/sold 683 options to buy
@ $4.9984, valued at
$3.4k
|
|
| 08/11/2023 |
4
| Oesterle Stephen N. (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 683 options to buy
@ $6.6439, valued at
$4.5k
Disposed/sold 683 options to buy
@ $4.9984, valued at
$3.4k
Disposed/sold 4,273 options to buy
@ $7.51, valued at
$32.1k
|
|
| 08/11/2023 |
4
| Shaff Eric D. (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 683 options to buy
@ $6.6439, valued at
$4.5k
Disposed/sold 683 options to buy
@ $4.9984, valued at
$3.4k
|
|
| 08/11/2023 |
4
| RUFFOLO ROBERT R (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 683 options to buy
@ $6.6439, valued at
$4.5k
Disposed/sold 683 options to buy
@ $4.9984, valued at
$3.4k
Disposed/sold 3,754 options to buy
@ $7.51, valued at
$28.2k
|
|
| 08/11/2023 |
4
| Cox John (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 341 shares
@ $0
Disposed/sold 683 options to buy
@ $6.6439, valued at
$4.5k
Disposed/sold 683 options to buy
@ $4.9984, valued at
$3.4k
|
|
| 08/11/2023 |
4
| Kowalsky Matthew Paul (CHIEF OF STAFF AND CLO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 1,925 shares
@ $0
Disposed/sold 12,690 options to buy
@ $0.75, valued at
$9.5k
|
|
| 08/11/2023 |
4
| Patel Kavita (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 683 options to buy
@ $6.6439, valued at
$4.5k
Disposed/sold 683 options to buy
@ $4.9984, valued at
$3.4k
|
|
| 08/11/2023 |
4
| Ashton-Rickardt Philip (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 8,845 options to buy
@ $0.75, valued at
$6.6k
|
|
| 08/11/2023 |
4
| Yuan Qing Sarah (CTOO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 2,884 shares
@ $0
Disposed/sold 8,846 options to buy
@ $0.75, valued at
$6.6k
|
|
| 08/11/2023 |
4
| Vivaldi Coelho Rogerio (PRESIDENT AND CEO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 12,169 shares
@ $0
Disposed/sold 35,382 options to buy
@ $0.75, valued at
$26.5k
|
|
| 08/11/2023 |
4
| Pontes Josias (CFO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Disposed/sold 3,504 shares
@ $0
Disposed/sold 10,767 options to buy
@ $0.75, valued at
$8.1k
|
|
| 07/27/2023 |
4
| Yuan Qing Sarah (CTOO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Exercised 2,884 options to buy
@ $19.24, valued at
$55.5k
|
|
| 07/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/01/2023 |
4
| Kowalsky Matthew Paul (CHIEF OF STAFF AND CLO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Granted 165,000 options to buy
@ $1.09, valued at
$179.9k
|
|
| 03/01/2023 |
4
| Vivaldi Coelho Rogerio (PRESIDENT AND CEO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Granted 460,000 options to buy
@ $1.09, valued at
$501.4k
|
|
| 03/01/2023 |
4
| Pontes Josias (CFO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Granted 140,000 options to buy
@ $1.09, valued at
$152.6k
|
|
| 03/01/2023 |
4
| Ashton-Rickardt Philip (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Granted 115,000 options to buy
@ $1.09, valued at
$125.4k
|
|
| 03/01/2023 |
4
| Yuan Qing Sarah (CTOO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Granted 115,000 options to buy
@ $1.09, valued at
$125.4k
|
|
| 05/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/27/2022 |
4
| Story Brooke (Director) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Granted 8,888 options to buy
@ $0.7632, valued at
$6.8k
|
|
| 05/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/04/2022 |
4
| Yuan Qing Sarah (CTOO) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Granted 120,000 options to buy
@ $1.48, valued at
$177.6k
|
|
| 02/22/2022 |
4
| Ashton-Rickardt Philip (CHIEF SCIENTIFIC OFFICER) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Granted 90,000 options to buy
@ $1.48, valued at
$133.2k
|
|
| 02/22/2022 |
4
| Pontes Josias (ACTING CHIEF FINANCIAL OFFICE) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Granted 60,000 options to buy
@ $1.48, valued at
$88.8k
|
|
| 02/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/22/2022 |
4
| Orfali May (CHIEF MEDICAL OFFICER) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Granted 10,000 options to buy
@ $1.48, valued at
$14.8k
|
|
| 01/04/2022 |
4
| Pontes Josias (VP, HEAD OF FINANCE) has filed a Form 4 on Sigilon Therapeutics, Inc.|
Txns:
| Granted 65,000 options to buy
@ $3.03, valued at
$197k
|
|
|
|
|